Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02938013 · ClinicalTrials.gov registry record · Phase 4
deLIVER: Direct Acting Antiviral Effects on the Liver
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT02938013: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT02938013 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 15 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02938013, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
Primary Outcome
Estimate the total number of HCV-infected Hepatocytes (virus burden) for each participant between pre-treatment liver biopsy and post treatment liver biopsy samples using HCV Quantitative real time PCR. Comparison of total number of HCV-infected Hepatocytes (virus burden) were reported between HCV mono infection and co infection groups.
Interventions
- DRUG Sofosbuvir/Velpatasvir (SOF/VEL)
- DRUG Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-09-30 |
| Phase | Phase 4 |
What the finished NCT02938013 record still lists
NCT02938013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir/Velpatasvir (SOF/VEL) is the first listed.
NCT02938013 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02938013 about?
NCT02938013 is a clinical study titled "deLIVER: Direct Acting Antiviral Effects on the Liver". Open-label, partially-randomized plasma and liver sampling study to assess hepatitis C virus (HCV) kinetics during treatment with two (Sofosbuvir/Velpatasvir) or three (Sofosbuvir/Velpatasvir/Voxilaprevir) direct acting antivirals (DAAs)
What is the current status of trial NCT02938013?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2017-01. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT02938013?
The interventions under investigation include: Sofosbuvir/Velpatasvir (SOF/VEL) (DRUG), Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX] (DRUG).
Who is sponsoring clinical trial NCT02938013?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02938013's enrollment target sits among peer trials
15 1880th of 2000 higher than 100 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia